

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 45807

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

Bouché O *et al.* Skin toxicities with panitumumab treatment

Olivier Bouché, Meher Ben Abdelghani, Jean-Luc Labourey, Simon Tribby, René-Jean Bensadoun, Thomas Jouary, Gaétan Des Guetz

Abstract

Match Overview

| | | |
|---|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1 | Internet 23 words crawled on 04-Mar-2014 www.nice.org.uk | 1% |
| 2 | Internet 17 words crawled on 17-Jan-2015 www.blogspan.net | <1% |
| 3 | Internet 10 words crawled on 29-Sep-2010 www.foxtrot.bham.ac.uk | <1% |
| 4 | Crossref 10 words Melanie Kripp, Nicole Prasnikar, Ursula Vehling-Kaiser, Julia Quidde et al. "AIO LQ-0110: a randomized phase II trial com | <1% |
| 5 | Internet 10 words crawled on 31-Aug-2017 kce.fgov.be | <1% |
| 6 | Crossref 10 words Khoudri, Ibtissam, Fatima Z. Lamchahab, Nadia Ismaili, Karim a Senouci, Badredine Hassam, and Redouane Abouqal. "Me | <1% |

找到约 54,400 条结果 (用时 0.50 秒)

Google 学术 : Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

... of life in patients with metastatic colorectal cancer - Lacouture - 被引用次数 : 356

... chemotherapy-refractory metastatic colorectal cancer - Van Cutsem - 被引用次数 : 1990

... efficacy in patients with metastatic colorectal cancer - Amado - 被引用次数 : 3188

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC ...

<https://clinicaltrials.gov/ct2/show/NCT00332163> ▼ 翻译此页

A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.

[PDF] Panitumumab and Cetuximab Toxicity Management Guidelines

<https://www.albertahealthservices.ca/.../cancer/if-hp-cancer-guide-panitumu...> ▼ 翻译此页

These guidelines have been created to ensure the safe administration of Panitumumab or Cetuximab (anti-EGFR therapy) to patients with advanced colorectal cancer in Alberta. Anti-EGFR therapy is indicated only for use in patients with KRAS, NRAS, and BRAF wild-type metastatic colorectal cancer.

A review of cutaneous toxicities from targeted therapies in the ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712297/> ▼ 翻译此页

作者 : C Urban - 2013 - 被引用次数 : 19 - 相关文章

Cetuximab and panitumumab are intravenous monoclonal antibody EGFR inhibitors. ... Panitumumab was first FDA-approved in 2006 for the treatment of EGFR-expressing metastatic colorectal cancer. The most common cutaneous toxicity resulting from treatment with EGFR inhibitors is the development of an acneiform eruption.

找到约 69,600 条结果 (用时 0.52 秒)

Google 学术 : Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

... of life in patients with metastatic colorectal cancer - Lacouture - 被引用次数 : 357

... with previously treated metastatic colorectal cancer - Hecht - 被引用次数 : 220

... for first-line treatment of metastatic colorectal cancer - Berlin - 被引用次数 : 111

[PDF] Managing Toxicities Associated With Colorectal Cancer ...

<https://cjon.ons.org/file/2176/download> ▼ 翻译此页

At a Glance. Advances in the treatment of metastatic colorectal cancer. + have given ... toxicities that may be encountered during treatment but also to identify and reduce skin toxicities to panitumumab by about 50% (Lacouture et al., 2009).

[PDF] Panitumumab and Cetuximab Toxicity Management Guidelines

<https://www.albertahealthservices.ca/.../cancer/if-hp-cancer-guide-panitumu...> ▼ 翻译此页

patients with advanced colorectal cancer in Alberta. ... is indicated only for use in patients with KRAS, NRAS, and BRAF wild-type metastatic colorectal ... The STEPP Trial suggests that, when compared to reactive skin treatment, "pre-emptive" ...

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC ...

<https://clinicaltrials.gov/ct2/show/NCT00332163> ▼ 翻译此页

A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.

Management of skin rash during egfr-targeted monoclonal antibody ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644628/> ▼ 翻译此页

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 58,400 条结果 (用时 0.54 秒)

Google 学术: Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

... of life in patients with metastatic colorectal cancer - Lacouture - 被引用次数: 357

... with previously treated metastatic colorectal cancer - Hecht - 被引用次数: 220

... for first-line treatment of metastatic colorectal cancer - Berlin - 被引用次数: 111

[PDF] Panitumumab and Cetuximab Toxicity Management Guidelines

<https://www.albertahealthservices.ca/.../cancer/if-hp-cancer-guide-panitumu...> ▼ 翻译此页

These guidelines have been created to ensure the safe administration of Panitumumab or Cetuximab (anti-EGFR therapy) to patients with advanced colorectal cancer in Alberta. Anti-EGFR therapy is indicated only for use in patients with KRAS, NRAS, and BRAF wild-type metastatic colorectal cancer.

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC ...

<https://clinicaltrials.gov/ct2/show/NCT00332163> ▼ 翻译此页

A comparison of prophylactic treatment with reactive treatment for skin toxicity observed in patients with metastatic colorectal cancer (mCRC) who are receiving second-line irinotecan-based chemotherapy concomitantly with panitumumab.

Management of skin rash during egfr-targeted monoclonal antibody ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644628/> ▼ 翻译此页

作者: B Melosky - 2009 - 被引用次数: 126 - 相关文章

In several analyses, both the presence and intensity of skin toxicity predicted objective tumour response in patients treated with cetuximab or panitumumab in mCRC. ... Overall survival by severity of skin rash in patients with third-line metastatic colorectal cancer receiving panitumumab.

Successful long-term management of a patient with late-stage ... - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/20189054> ▼ 翻译此页

作者: E Seront - 2010 - 被引用次数: 14 - 相关文章

Cancer Treat Rev. ... patient with late-stage metastatic colorectal cancer treated with panitumumab.